Literature DB >> 24323728

Alzheimer's silent partner: cerebral amyloid angiopathy.

Tanya L Cupino1, Matthew K Zabel.   

Abstract

Alzheimer's disease (AD) is the most common form of dementia, which completely lacks a viable, long-term therapeutic intervention. This is partly due to an incomplete understanding of AD etiology and the possible confounding factors associated with its genotypic and phenotypic heterogeneity. Cerebral amyloid angiopathy (CAA) is a common, yet frequently overlooked, pathology associated with AD. CAA manifests with deposition amyloid-beta (Aβ) within the smooth muscle layer of cerebral arteries and arterioles. The role of Aβ in AD and CAA pathophysiology has long been controversial. Although it has demonstrated toxicity at super-physiological levels in vitro, Aβ load does not necessarily correlate with cognitive demise in humans. In this review, we describe the contributions of CAA to AD pathophysiology and important pathomechanisms that may lead to vascular fragility and hemorrhages. Additionally, we discuss the effect of Aβ on smooth muscle cell phenotype and viability, especially in terms of the complement cascade.

Entities:  

Mesh:

Year:  2013        PMID: 24323728     DOI: 10.1007/s12975-013-0309-7

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  89 in total

1.  Incidence of cerebrovascular lesions in Alzheimer's disease: a postmortem study.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  Acta Neuropathol       Date:  2002-10-22       Impact factor: 17.088

2.  Toxicity of Dutch (E22Q) and Flemish (A21G) mutant amyloid beta proteins to human cerebral microvessel and aortic smooth muscle cells.

Authors:  Z Wang; R Natté; J A Berliner; S G van Duinen; H V Vinters
Journal:  Stroke       Date:  2000-02       Impact factor: 7.914

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

Authors:  Margaret M Racke; Laura I Boone; Deena L Hepburn; Maia Parsadainian; Matthew T Bryan; Daniel K Ness; Kathy S Piroozi; William H Jordan; Donna D Brown; Wherly P Hoffman; David M Holtzman; Kelly R Bales; Bruce D Gitter; Patrick C May; Steven M Paul; Ronald B DeMattos
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

5.  Screening for familial APP mutations in sporadic cerebral amyloid angiopathy.

Authors:  Alessandro Biffi; Anna Plourde; Yiping Shen; Robert Onofrio; Eric E Smith; Matthew Frosch; Claudia M Prada; James Gusella; Steven M Greenberg; Jonathan Rosand
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

6.  Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes.

Authors:  H V Vinters; J J Gilbert
Journal:  Stroke       Date:  1983 Nov-Dec       Impact factor: 7.914

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Incidence of stroke in people with Alzheimer disease: a national register-based approach.

Authors:  Anna-Maija Tolppanen; Piia Lavikainen; Alina Solomon; Miia Kivipelto; Hilkka Soininen; Sirpa Hartikainen
Journal:  Neurology       Date:  2013-01-02       Impact factor: 9.910

9.  Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study.

Authors:  Tom Jeerakathil; Philip A Wolf; Alexa Beiser; Joseph Massaro; Sudha Seshadri; Ralph B D'Agostino; Charles DeCarli
Journal:  Stroke       Date:  2004-06-24       Impact factor: 7.914

Review 10.  Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?

Authors:  Haythum O Tayeb; Evan D Murray; Bruce H Price; Frank I Tarazi
Journal:  Expert Opin Biol Ther       Date:  2013-04-10       Impact factor: 4.388

View more
  13 in total

1.  Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease.

Authors:  Junling Yang; Jinghong Kou; Robert Lalonde; Ken-Ichiro Fukuchi
Journal:  Brain Behav Immun       Date:  2017-05-17       Impact factor: 7.217

Review 2.  The role of autophagy in vascular biology.

Authors:  Samuel C Nussenzweig; Subodh Verma; Toren Finkel
Journal:  Circ Res       Date:  2015-01-30       Impact factor: 17.367

Review 3.  An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.

Authors:  Xiaoling Zhou; Yifei Li; Xiaozhe Shi; Chun Ma
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

Review 4.  Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood-brain barrier.

Authors:  Stephen B Hladky; Margery A Barrand
Journal:  Fluids Barriers CNS       Date:  2018-10-19

Review 5.  Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.

Authors:  Marla Rivera-Oliver; Manuel Díaz-Ríos
Journal:  Life Sci       Date:  2014-02-13       Impact factor: 5.037

Review 6.  Caffeine: cognitive and physical performance enhancer or psychoactive drug?

Authors:  Simone Cappelletti; Daria Piacentino; Piacentino Daria; Gabriele Sani; Mariarosaria Aromatario
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

Review 7.  Intracerebral haemorrhage in Down syndrome: protected or predisposed?

Authors:  Lewis Buss; Elizabeth Fisher; John Hardy; Dean Nizetic; Jurgen Groet; Laura Pulford; André Strydom
Journal:  F1000Res       Date:  2016-05-12

Review 8.  Hydrogen therapy: from mechanism to cerebral diseases.

Authors:  Cheng-Lin Liu; Kai Zhang; Gang Chen
Journal:  Med Gas Res       Date:  2016-04-04

9.  Cerebrovascular reactivity in cerebral amyloid angiopathy, Alzheimer disease, and mild cognitive impairment.

Authors:  Aaron R Switzer; Ikreet Cheema; Cheryl R McCreary; Angela Zwiers; Anna Charlton; Ana Alvarez-Veronesi; Ramnik Sekhon; Charlotte Zerna; Randall B Stafford; Richard Frayne; Bradley G Goodyear; Eric E Smith
Journal:  Neurology       Date:  2020-07-08       Impact factor: 9.910

Review 10.  Neurovascular Unit Dysfunction and Neurodegenerative Disorders.

Authors:  Xing Yu; Caihong Ji; Anwen Shao
Journal:  Front Neurosci       Date:  2020-04-29       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.